KRAS and neoplasm: It has been proven that binding of G12C SII-P covalent inhibitors reshapes conformation of switch regions to favor GDP-binding by abrogating the interactions between γ-phosphate and Switch II region.282 As such, the KRAS mutant is retained in the inactive “off” state and the KRASG12C-driven tumor growth is inhibited.